Form 4: Metagenomi CMO Sells Shares to Cover Tax Obligations Following RSU Vesting

Metagenomi's Chief Medical Officer, Sarah B. Noonberg, sold 5,239 shares of common stock at $1.75 per share on June 6, 2025, to satisfy tax withholding obligations upon the vesting of restricted stock units.

Summary

• Sarah B. Noonberg, Chief Medical Officer of Metagenomi, Inc. (MGX), reported a sale of 5,239 shares of common stock.
• The transaction occurred on June 6, 2025, with shares sold at a price of $1.75 each.
• Following this transaction, Ms. Noonberg beneficially owns 109,135 shares of Metagenomi common stock.
• The sale was not a discretionary trade but an automatic transaction to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted on April 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were sold, it was a non-volitional transaction for tax purposes following the vesting of restricted stock units, which is a positive event for the executive. It does not indicate a lack of confidence in the company.

Positives

• The underlying event, the vesting of restricted stock units (RSUs), represents a positive compensation event for the Chief Medical Officer.

Negatives

• The sale of shares, while non-volitional, slightly increases the number of shares in the market.

Risks

• While this specific sale is for tax purposes, any insider sale can sometimes be misinterpreted by the market as a lack of confidence, potentially leading to short-term negative sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• "These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."

Industry Context

This specific insider transaction is a routine compliance filing and does not inherently reflect broader industry trends. Tax-related sales upon RSU vesting are common across all industries, particularly in high-growth sectors like biotechnology where equity compensation is prevalent.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale was non-volitional and for tax purposes, not signaling a change in management's confidence. It represents a very small fraction of outstanding shares.
• Employees: The vesting of RSUs is a positive for the executive, demonstrating the company's compensation structure.

Next Steps

• The document does not outline any specific future actions, events, or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Keywords

Metagenomi, MGX, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Sarah B. Noonberg, Chief Medical Officer